Skip to content

CorMedix CRMD Accounts Payable

Accounts Payable at other companies

Pfizer logo
PfizerPFE
$4.51B-14.0%
Merck & Co. logo
Merck & Co.MRK
$3.86B+2.1%
Merit Medical Systems logo
Merit Medical SystemsMMSI
$67.85M+6.4%
ITG
Integer HoldingsITGR
$115M+2.7%
IAR
Integra LifeSciencesIART
$87.95M-3.7%
Emergent Biosolutions logo
Emergent BiosolutionsEBS
$39.5M-32.0%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's accounts payable?
CorMedix (CRMD) reported accounts payable of $12.83M in Q1 2026.
How has CorMedix's accounts payable changed year-over-year?
CorMedix's accounts payable increased by 563.5% year-over-year, from $1.93M to $12.83M.
What is the long-term trend for CorMedix's accounts payable?
Over 5 years (2020 to 2025), CorMedix's accounts payable has grown at a 47.5% compound annual growth rate (CAGR), from $1.13M to $7.88M.
What does accounts payable mean?
Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.